Clinical Trials Browser

Lymphoma × Azacitidine × 90 days × Clear all

NCT04588922 2026-05-01

Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML

Phase 1/2 Recruiting

LymphoidOther hematologic neoplasm

Lymphoma, Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myeloid, Acute, Hematologic Neoplasms